Semler Scientific

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Semler Scientific posts record revenue and profit growth in Q4

Semler Scientific delivered robust financial performance in Q4 2022, marked by record revenue, profit growth, and a strong cash position.
The company's strengths lie in its revenue diversification, profitability improvement, and strategic leadership transition.
Challenges include managing operating expenses, sustaining revenue growth across segments, and ensuring a smooth CEO transition.
Opportunities for Semler include expansion, innovation in healthcare technologies, and leveraging market demand for its services for future growth.

Semler Scientific achieves record Q1 earnings amidst strategic growth

Semler Scientific delivered robust financial performance in Q1 2023, marked by record revenue and pre-tax net income, underpinned by strong liquidity.
The company's strategic focus on governance, product innovation, and confidence in product benefits positions it well to navigate challenges and seize growth opportunities.
Despite cost management challenges and regulatory uncertainties, Semler's resilience, financial strength, and commitment to innovation bode well for future success.

Semler Scientific reports record revenue and profit growth in Q2

Semler Scientific's Q2 2023 performance showcased robust revenue growth, driven by successful QuantaFlo sales, and a significant increase in pre-tax net income.
The company's strategic initiatives, including leadership changes, product introductions, and operational streamlining, demonstrate a focus on sustainable growth and innovation.
While facing challenges such as cost management and workforce reduction, Semler Scientific is well-positioned to leverage opportunities in market expansion, technology advancements, and clinical benefits delivery.

Semler Scientific excels in Q3 with strong revenue growth

Semler Scientific's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and growth opportunities. The company's focus on innovation and market expansion positions it well for future success.

Semler Scientific reports solid Q4 earnings, eyes growth in cardiovascular diagnosis

Semler Scientific's Q4 2023 earnings call showcased positive financial performance, strategic growth initiatives, and a commitment to innovation in cardiovascular disease diagnosis.
Despite challenges such as operating expenses and fixed fee revenue decline, the company's adaptability and focus on clinical benefits position it well for future opportunities.
Analyst inquiries and executive responses highlighted a strong emphasis on efficiency improvements, market adaptability, and regulatory clearances for continued growth.

Semler Scientific reports earnings growth, eyes new product clearance

Semler Scientific's Q1 2024 performance showed growth in earnings and effective cost management.
While facing revenue challenges, the company is strategically positioned to capitalize on growth opportunities.
With a focus on innovation and market expansion, Semler aims to drive future revenue growth.
The company's strong financial position and strategic initiatives position it well for future success.

Semler Scientific adopts bitcoin treasury, reports stable Q2 performance

Semler Scientific's Q2 2024 performance reflects a strategic shift towards bitcoin as a treasury asset and a focus on core business operations.
While facing revenue challenges and cost management needs, the company's financial strength and flexibility position it well for future growth.
Opportunities lie in leveraging debt securities for expansion and capitalizing on the potential of bitcoin as a long-term investment.

Semler Scientific reports robust Q3 earnings, diversifies into Bitcoin

Semler Scientific's Q3 2024 performance reflects resilience in income generation and prudent cost control measures.
The company's strategic focus on Bitcoin acquisitions and product innovation positions it for potential growth and market leadership.
While facing revenue challenges and financial risks, Semler's exploration of financing options and regulatory compliance efforts signal a proactive stance.
Opportunities lie in leveraging operational strength for expansion, diversifying investment strategies, and capitalizing on early disease diagnosis capabilities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Eric Semler Appointed as Chairman SANTA CLARA, Calif. , April 19, 2023 /PRNewswire/ -- - Semler Scientific, Inc. (Nasdaq: SMLR) today announced that Eric Semler and William H.C.

Semler Scientific Announces Appointment of Eric Semler and William Chang as Directors

SANTA CLARA, Calif. , April 5, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Wayne T.

Semler Scientific to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SANTA CLARA, Calif. , April 3, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services (CMS) 2024 Medicare Advantage and Part D Final Rate Announcement.

Semler Scientific Comments on CMS Risk Adjustment Changes in the 2024 Medicare Advantage and Part D Final Rate Announcement

Semler Scientific, Inc. (NASDAQ:SMLR ) Q4 2022 Results Conference Call March 21, 2023 4:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO, Corporate Secretary Wayne Pan - New CEO Renae Cormier - Head, Corporate Communication and Business Strategy Andrew Weinstein - SVP, Finance & Accounting Dennis Rosenberg - Chief Marketing Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2022 Fourth Quarter and Full Year Financial Results Conference Call. All participants will be in listen-only mode [Operator Instructions].

Semler Scientific, Inc. (SMLR) Q4 2022 Earnings Call Transcript

2022 Q4 and Full Year highlights compared to the corresponding period of 2021: Fourth quarter revenue was $13.8 million, an increase of 20% Fourth quarter net income was $3.2 million, an increase of 113% Full year revenue was $56.7 million, an increase of 7% Full year net income was $14.3 million, a decrease of 17% Cash at December 31, 2022 increased to $43.1 million, including short-term investments Corporate update: CEO transition announced; see separate press release issued today SANTA CLARA, Calif. , March 21, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months and year ended December 31, 2022.

Semler Scientific Reports Fourth Quarter and Full Year 2022 Financial Results

SANTA CLARA, Calif. , March 21, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, announces that Doug Murphy-Chutorian, M.D.

Semler Scientific Names Wayne T. Pan, M.D., Ph.D.

SANTA CLARA, Calif. , March 1, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers (HCPs), today announced the publication of a study in the peer-reviewed Journal of Preventive Medicine with data supporting the use of QuantaFlo as an aid to measure hemodynamics related to heart dysfunction (HD).

Semler Announces Clinical Study Published Using QuantaFlo® as an Aid for Diagnosis of Heart Dysfunction in the Primary Care Setting

The recent drastic drop in stock price is grossly exaggerated. Value proposition of QuantaFlo, Semler's main product, remains intact.

Semler Scientific: Value Proposition Still Intact

The CMS advanced notice for Medicare advantage for the year 2024 removed the PAD HCC code QuantaFlo uses. This could negatively impact QuantaFlo's usage. Semler's stock crashed as a result.

Semler Stock Crashes Due To Potential Medicare Advantage Risk

SANTA CLARA, Calif. , Dec. 14, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that a study was published in the peer-reviewed AJPM Focus with data collected using the company's QuantaFlo® PAD test under real-world conditions, illustrating the benefits of PAD in-home screening.

Major Clinical Study Using Semler's QuantaFlo® for Medicare Advantage Beneficiaries, Demonstrates that National, In-Home Screening for Peripheral Artery Disease (PAD) is Feasible

SANTA CLARA, Calif. , Dec. 12, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced an up to $5.0 million investment in privately-held Monarch Medical Technologies, LLC (Monarch) through the purchase of a senior secured convertible promissory note.

Semler Announces Investment in Monarch Medical Technologies

Semler Scientific Inc. (SMLR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging 30.3% in 4 Weeks, Here's Why the Trend Might Reverse for Semler Scientific Inc. (SMLR)

The medical diagnostic company plunged after it gave soft guidance for the fourth quarter.

Why Semler Scientific Plunged 37% This Morning

Semler Scientific, Inc. (NASDAQ:SMLR ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO, Corporate Secretary Dennis Rosenberg - Chief Marketing Officer Renae Cormier - Head, Corporate Communication and Business Strategy Andrew Weinstein - SVP, Finance & Accounting Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marc Wiesenberger - B. Riley Securities Operator Hello and welcome to the Semler Scientific Third Quarter 2022 Financial Results Call.

Semler Scientific, Inc. (SMLR) Q3 2022 Earnings Call Transcript

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 24.32% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Semler Scientific Inc. (SMLR) Q3 Earnings Beat Estimates

2022 Q3 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenue was $14.0 million, same as the prior year period Net income was $3.7 million, or $0.55 per basic share and $0.46 per diluted share, compared to $4.2 million, or $0.61 per basic share and $0.51 per diluted share Cash and cash equivalents at September 30, 2022 increased to $45.5 million from $35.9 million SANTA CLARA, Calif. , Nov. 1, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and nine months ended September 30, 2022.

Semler Reports Third Quarter and Year-to-Date 2022 Financial Results

SANTA CLARA, Calif. , Oct. 19, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the third quarter and first nine months ended September 30, 2022, after the close of U.S. financial markets on Tuesday, November 1, 2022.

Semler to Report Third Quarter and First Nine Months of 2022 Financial Results and Host Conference Call on November 1, 2022

Asensus Surgical

Shockwave Medical

The Zacks Medical - Instruments industry is growing on R&D investments. SWAV, SMLR and ASXC are set to gain the most.

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

SANTA CLARA, Calif. , Aug. 31, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced, Head of Corporate Communications and Business Strategy, Renae Cormier, will participate in the following investor conferences: H.C.

Semler Scientific to Present at Upcoming Investor Conferences

Why Semler Scientific Stock Is Skyrocketing Today

Semler Scientific, Inc. (NASDAQ:SMLR ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO, Corporate Secretary & Director Renae Cormier - Head, Corporate Communication and Business Strategy Andrew Weinstein - SVP, Finance & Accounting Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marc Wiesenberger - B. Riley Securities Operator Good afternoon, and welcome to the Semler Scientific Second Quarter 2022 Financial Results Conference Call.

Semler Scientific, Inc. (SMLR) CEO Douglas Murphy-Chutorian on Q2 2022 Results - Earnings Call Transcript

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 27.50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Semler Scientific Inc. (SMLR) Q2 Earnings and Revenues Surpass Estimates

2022 Q2 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.8 million, an increase of 4%, compared to $14.3 million Net income was $4.1 million, or $0.60 per basic share and $0.51 per diluted share, compared to $6.7 million, or $1.00 per basic share and $0.83 per diluted share Cash and cash equivalents at June 30, 2022 increased to $40.0 million from $28.5 million SANTA CLARA, Calif. , Aug. 2, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and six months ended June 30, 2022.

Semler Reports Second Quarter and First Half of 2022 Financial Results

Semler Scientific's stock value has fallen from about $150 per share in November of 2021 to around $30 per share. Yet, the company continues to report growth and is profitable. I believe the market has taken the selling too far and is overlooking the company's unique product and intrinsic valuations.

Semler Scientific: Growth, Profits, And Valuation Models Support A Buy

SANTA CLARA, Calif. , July 21, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the second quarter and first half ended June 30, 2022, after the close of U.S. financial markets on Tuesday, August 2, 2022.

News for Semler Scientific Stock (SMLR)